

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SinoMab BioScience Limited**

**中國抗體製藥有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 3681)**

**VOLUNTARY ANNOUNCEMENT  
IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE**

Reference is made to the announcements of SinoMab BioScience Limited (中國抗體製藥有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on 14 November 2019, 29 January 2020, 29 June 2020, 1 September 2020, 15 January 2021, 24 June 2021, 23 July 2021, 7 February 2022 and 20 April 2022 in relation to the latest research and development progress of one of the Group’s key products, SN1011.

The board of directors (the “**Board**”) of the Company is pleased to announce that on 6 June 2022, an Investigational New Drug application (“**IND**”, for neuromyelitis optica spectrum disorder (“**NMOSD**”)) for SN1011 has been filed with and accepted by the Center for Drug Evaluation (the “**CDE**”) of the National Medical Products Administration of China (the “**NMPA**”). The Company plans to initiate the Phase II clinical study in China upon approval of the present IND. The present IND submission, once granted, will enable the Company to conduct comprehensive clinical development program in China which leads to indication for treatment of NMOSD.

SN1011 is the Company’s third generation, covalent reversible BTK inhibitor designed for higher selectivity, superior efficacy and improved safety for the long-term treatment of systemic lupus erythematosus, pemphigus vulgaris, multiple sclerosis, rheumatoid arthritis, and other immunological diseases. SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety. SN1011 had obtained three IND approval (for systemic lupus erythematosus (SLE), pemphigus vulgaris (PV) and multiple sclerosis (MS)) from the NMPA.

By Order of the Board  
**SinoMab BioScience Limited**  
**Dr. Shui On LEUNG**

*Executive Director, Chairman and Chief Executive Officer*

Hong Kong, 9 June 2022

*As at the date of this announcement, the executive director is Dr. Shui On LEUNG, the non-executive directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.*